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Background: Isolated limb infusion (ILI) using cytotoxic agents has been demonstrated to be 
an effective and less invasive alternative modality than isolated limb perfusion for the treatment 
of melanoma localized to a limb. Percutaneous catheters were inserted into the axial artery and 
vein of the affected limb while using a pneumatic cuff to restrict limb vascular flow proximally 
to “isolate” the limb from the body and enable delivery of high-dose intra-arterial chemotherapy 
selectively to the limb. The ILI technique was developed at the Sydney Melanoma Unit (now 
renamed the Melanoma Institute Australia), and only a few other centers have reported separate 
results. We report our early results using the ILI technique for management of locally recurrent 
surgically nonresectable melanoma.
Methods and results: Twenty-eight ILI procedures were performed in 20 patients treated with 
one or more procedures between 1997 and 2007. Patient parameters and clinical responses were 
evaluated. The median follow-up duration was 15.9 months after the first ILI, with an overall 
response rate after one or more infusions of 70%, of which 35% were complete responders and 
35% were partial responders, with a further 20% showing stable disease, giving a “clinically 
significant” response rate of 90%. After one ILI (n = 20), the overall response rate was 70%, 
with 20% complete responders and 50% partial responders, and 20% with stable disease. Low 
limb toxicities were generally observed, and no amputations were required.
Conclusion: ILI chemotherapy is a useful technique, which can be readily repeated for control 
of melanoma in the limb. It is generally well tolerated, and is capable of achieving a cure, delayed 
progression, or effective palliation in selected cases. The longest survivors in this series were 
8 and 10 years from the last ILI.
Keywords: metastatic melanoma, melphalan, actinomycin-D, regional therapy, intra-arterial 
infusion
Introduction
The incidence of melanoma in Australian men and women increased by 42% and 
18%, respectively, from 1991 to 2009,1 bringing with it a corresponding increase in 
the number of patients presenting with local recurrences following initial surgical 
excision. A study from the Sydney Melanoma Unit examining 4704 American Joint 
Committee on Cancer stage I and II patients reported a recurrence rate of 18.6% in 
873 patients, of which 10.9% were local and 9.9% in-transit in type, over a median 
follow-up duration of 5.3 years after initial excision of primary melanoma.2 Many 
of these are related to risk factors of the primary melanoma, such as high Breslow 
thickness or ulceration.
The modalities of treatment for patients with localized recurrence of limb mela-
noma are numerous, including local surgical excision, laser ablation, local injection, 
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cryotherapy, and vaccine therapy. However, when metastases 
are numerous or bulky, these options are limited and other 
techniques should be considered, such as regional chemother-
apy, radiotherapy, or systemic chemotherapy. Chemotherapy 
doses achievable using standard systemic chemotherapy 
are lowered due to risk of systemic side effects; however, 
higher doses of chemotherapy can be delivered to the limb 
if it is vascularly “isolated” from the systemic circulation. 
Isolated limb perfusion was developed in the 1950s3 and 
used in many centers worldwide, but carries higher risks 
of morbidity and mortality because of its highly invasive 
nature. It requires use of vascular dissection and clamping 
as well as an extracorporeal bypass pump circuit, making 
it a complex and costly procedure. Overall response rates 
reported using isolated limb perfusion range from 71% to 
88%, with complete response rates of 12%–73%.4–11 This 
wide range in complete response rates is likely related to 
differences in patient selection factors between studies. 
Known complications after isolated limb perfusion include 
compartment syndrome, neuropathy, infection, and arterial 
or venous thrombosis.4–18
Over the last two decades, isolated limb infusion (ILI) 
has been used at the Sydney Melanoma Unit (now known 
as the Melanoma Institute Australia) as an alternative to 
isolated limb perfusion. ILI has the advantage of being a 
much simpler procedure, circumventing the need for com-
plex bypass, extensive surgical dissection, and long operat-
ing times, whilst being well tolerated and, if required, readily 
repeated, even in the elderly. High doses of chemotherapy, 
above systemically tolerable levels, can be delivered selec-
tively to the affected limb, without leakage into the systemic 
circulation. Clinical response rates using ILI have been 
demonstrated to be comparable with those obtained using 
isolated limb perfusion.15,16
Patients and methods
Informed consent was obtained from all patients and the 
studies were approved by the Royal Adelaide Hospital 
human research ethics committee. Analysis was conducted 
on data from a total of 28 ILI procedures that were performed 
between July 1997 and May 2007 in 20 patients at the Royal 
Adelaide Hospital. The indication for treatment was recur-
rent lower or upper limb melanoma for which surgery was 
not feasible, presenting with either satellite or in-transit 
metastases and with or without previous surgically resected 
lymph node involvement. Patients with stage IV disease were 
treated for palliative purposes and were also included in this 
study to assess limb disease responses.
The technique used for ILI is shown in Figure 1 and have 
been detailed elsewhere.15 In summary, a nonoxygenated 
low-flow extracorporeal circuit was created using percutane-
ously inserted arterial and venous catheters (6 French and 8 
French, respectively). Under general anesthesia, the patient 
was systemically heparinized, followed by a rapid intra-
arterial bolus injection of papaverine, and then isolation 
of the disease-affected limb using an inflatable tourniquet, 
placed proximally, high on the limb. Rapid intra-arterial 
infusion of melphalan and actinomycin D followed. Using a 
high-flow, three-way stopcock valve, the infusate was manu-
ally circulated using a 60 mL syringe for up to 30 minutes. 
Blood warming coils were incorporated into this circuit to 
maintain limb temperature, and hot-air blankets were used 
to cover the patient’s limbs and body. Intramuscular and 
subcutaneous temperature probes were inserted into the 
limb for monitoring the temperatures throughout the proce-
dure. Following circulation, the infusate was drained from 
the isolated circuit, discarded, and replaced by Hartmann’s 
solution to wash out the intravascular chemotherapeutic 
agent. Protamine was administered to reverse the hepa-
rinization and the catheters were removed. Pressure was 
applied to the puncture sites, followed by reversal of the 
general anesthetic.
Patients were restricted to bed rest with elevation of 
the treated limb for 48 hours following the procedure. 
Hourly limb observation, daily creatine kinase mea-
surements, and limb toxicity assessments were made 
using the scale published by Wieberdink et al19 (see 
Table 1).
Patients’ responses were clinically defined by World 
Health Organization criteria for reporting cancer treatment, 
where determinant measurements were taken not less than 
4 weeks apart.20 A complete response was defined by a 
100% reduction in tumor mass; a partial response was a 
reduction in tumor mass by over 50%; stable disease was 
a reduction of less than 50% or an increase in mass of no 
more than 25%; whilst progressive disease was defined as 
any increase in mass greater than 25%. Overall response 
was defined as the combined complete response and partial 
response rates. Response duration was defined as the time 
elapsed between the ILI procedure and the development 
of new or progressive disease. Assessment of response 
was conducted by the same clinician on each occasion 
with measurement comparisons pre-ILI and on subsequent 
follow-up.
The results were analyzed as follows: assessment after 
the initial ILI procedure for all patients to assess initial 
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outcome (n = 20); collectively for all patients, regardless of 
the number of ILI procedures performed, to assess overall 
outcome (n = 20); patients receiving a single ILI procedure 
alone (n = 15);  assessment of all ILI treatment episodes for 
all patients; and assessment of the toxicity of each ILI pro-
cedure (n = 28).
Statistical analysis
An ordinal regression model was used to determine any 
association between patient characteristics and clinical 
response. A statistically significant difference was assumed 
at a probability value of ,0.05. Statistical analyses were 
performed using Statistical Package for Social Sci-
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Figure 1 Isolated limb infusion circuit in a lower limb showing positioning of the tourniquet, arterial and venous catheters inserted in the ipsilateral (or contralateral) groin 
to reach approximately the level of the popliteal artery and vein, respectively, and the extracorporeal warmed circuit using a hand-driven syringe pump.
Table 1 Wieberdink grades19
Grade I no visible effect
Grade II Slight erythema and/or edema
Grade III Considerable erythema and/or edema
Grade IV Extensive epidermolysis and/or obvious damage to deep 
tissues with a threatened or actual compartment syndrome
Grade V Severe tissue damage necessitating amputation
Notes: Reprinted from Eur J Cancer Clin Oncol,18, Wieberdink J, Benckhuysen C, 
Braat RP, et al, Dosimetry in isolation perfusion of the limbs by assessment of 
perfused tissue volume and grading of toxic tissue reactions, 905–910. Copyright © 
1982, with permission from Elsevier.19
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patients received two ILI procedures, and three had triple ILI 
procedures. The relevant patient and tumor data are shown 
in Table 2. Of the 20 patients who received ILI therapy, 
19 involved the lower limb and one ILI was performed on 
the upper limb.
The median follow-up duration after the initial ILI for 
all 20 patients was 15.9 (2.7–121.4) months. The patient 
population consisted of 14 women and six men of median 
age 72.6 (32.4–97.2) years. Computed tomography scans 
were performed at the time of ILI. All patients had either 
local recurrences or in-transit melanoma metastases in the 
limb, of whom 11 had no lymph node involvement, eight 
had previous regional lymph node involvement, and one had 
evidence of possible small pulmonary metastases.
The median volume infused into lower limb tissue was 
6.75 (4.0–15.5) L, while the one case involving the upper limb 
had an infusion volume of 2.0 L. The median melphalan dose 
administered was 7.5 (6.0–13.3) mg per liter of tissue and 
the median actinomycin D dose was 50.0 (36.3–67.5) µg per 
liter of tissue. Median initial intramuscular and subcutaneous 
limb temperatures were 35.1°C (32.5°C–38.0°C) and 
34.5°C (19.4°C–36.4°C), respectively, with median final 
temperatures of 34.9°C (28.7°C–39.0°C) and 34.9°C 
(21.8°C–38.2°C), respectively.
Initial single ILI outcomes
Toxicity
There was one case of grade I limb toxicity (5%), 14 cases 
of grade II limb toxicity (70%), three cases of grade III 
limb toxicity (15%), and two cases of grade IV limb toxic-
ity (10%). No cases of grade V limb toxicity requiring limb 
amputation were observed. Of the two grade IV cases, one 
was considered to be a chemical cellulitis, which resolved 
without intervention. The other patient experienced severe 
local chemotherapy toxicity around the site of the catheter 
tips due to poor venous drainage subsequent to prior deep 
venous thrombosis years previously, but this was not declared 
until after the procedure, and required extensive debridement 
and grafting (longest bed stay). The median length of hospital 
stay for all patients was 8.5 (6–18) days.
Clinical responses
After clinical evaluation, there was an overall response rate 
of 70%, with a complete response rate of 20% and a partial 
response rate of 50%. Four patients were classified as having 
stable disease (20%), and if these were included, the overall 
“clinically significant” response rate was 90%. Another two 
patients were classed as having progressive disease (10%). In 
the four patients who achieved a complete response, only one 
has since developed further systemic disease; the median time 
from ILI until progression was 18.2 (4.1–45.7) months. Three of 
the four patients who achieved a complete response had regional 
lymph node involvement and nodal surgery prior to ILI and 
did not experience any recurrence. The other patient who had 
a complete response in the infused limb had stage IV disease, 
but did not experience limb recurrence. Of the ten patients 
who achieved a partial response, all but two have developed 
progressive or new disease, occurring after a median follow-up 
period of 7.3 (2.0–12.0) months after ILI. Of those ten patients 
with a partial response, eight were classified as having local or 
in-transit disease without regional nodal involvement, whilst 
the other two had regional nodal disease.
Overall final ILI outcomes
Toxicity
Limb toxicities after the final ILI for all patients (n = 20) 
were: grade 1, 5% (n = 1); grade 2, 75% (n = 15); grade 3, 
10% (n = 2); and grade 4, 10% (n = 2).
Clinical responses
After the final ILI for all patients, there was an overall 
response rate of 70%, with a complete response rate of 35% 
(n = 7) and a partial response rate of 35% (n = 7). Stable 
disease was seen in 20% of cases (n = 4) and progressive 
Table 2 Patient characteristics
Characteristics Patients, n (%)
OR, median (range)
Age, median (range) years 72 (32.5–97.3)
Breslow thickness (mm) 1.7 (0.4–10.0)
Gender
 Male 6 (30)
 Female 14 (70)
Stage (AJCC)
 IIIb 11 (55)
 IIIc 8 (40)
 IV 1 (5)
Limb
 Upper 1 (5)
 Lower 19 (95)
Site of disease
 Below knee 4 (20)
 Above knee 4 (20)
 Below/above knee 11 (55)
 Below elbow 1 (5)
Lesions (n)
 0–5 3 (15)
 5–10 3 (15)
 10–15 2 (10)
 15–20 2 (10)
 .20 4 (20)
 not determined 6 (30)
Abbreviations: AJCC, American Joint Committee on Cancer; OR, odds ratio.
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disease in 10% (n = 2). If stable disease was included, the 
overall “clinically significant” response rate was 90%.
Outcomes in patients receiving  
only one ILI procedure
Toxicity
Limb toxicities for this patient subset (n = 15) were: grade 1, 
6.7% (n = 1); grade 2, 73.3% (n = 11); grade 3, 6.7% (n = 1); 
and grade 4, 13.3% (n = 2).
Clinical responses
The overall response rate for patients who received one ILI 
alone was 66.6% (n = 15), with a complete response rate of 
26.6% (n = 4), a partial response rate of 40% (n = 6), stable 
disease in 26.6% (n = 4), and progressive disease in one 
patient (6.8%). If stable disease was included, the overall 
“clinically significant” response rate was 93.2%.
Assessment of all ILI therapy  
episodes for overall toxicity
Limb toxicity following all ILI procedures (n = 28) was: 
grade 1, 3.6% (n = 1); grade 2, 71.4% (n = 20); grade 3, 
17.8% (n = 5); and grade 4, 7.2% (n = 2). Of the 28 pro-
cedures, 19 (67.9%) showed raised creatine kinase levels 
postoperatively. The median duration until peak creatine 
kinase was four (1–6) days, while the median peak level was 
680.5 (30–27,650) Units/liter. Ordinal regression showed that 
the peak creatine kinase level had a statistically significant 
association with Wieberdink toxicity grade (P = 0.012). The 
peak creatine kinase level did not show any association with 
clinical response or disease-free interval (P . 0.05).
Discussion
Recurrence of melanoma in a limb represents a spectrum of 
disease, but is predominantly either cutaneous or subcutane-
ous, or a combination of both. Involvement of limb bones or 
muscle is rare, but can occur, sometimes associated with deep 
and large subcutaneous tumor deposits, and/or enlargement of 
lymph node metastases in the deep calf, popliteal, or epitro-
chlear regions. Bulky disease may occur if superficial deposits 
enlarge and/or become confluent. Essentially all cutaneous 
and subcutaneous recurrent melanoma arises from lymphatic 
metastatic spread that is in-transit to the regional lymph nodal 
basin. This fact was recognized in the 2001 and 2009 American 
Joint Committee on Cancer staging classification, where in-
transit lesions were classified as stage III melanoma.21 Despite 
this, local surgical resection of superficial limb deposits, in 
small numbers or appearing sequentially, is often surprisingly 
effective for control of recurrent disease of the limb, even in 
the longer term. However, there are difficult situations where 
melanoma metastases develop inexorably in a limb and are not 
amenable to standard local therapies.22 Systemic chemotherapy 
is usually ineffective for treatment of advanced melanoma 
recurrence in a limb, and radiotherapy may have an effect, but 
this is often unpredictable.23 Recent therapies, such as B-raf 
inhibitory antibodies, can have some effect, although this is 
often temporary or short-lived. Over half of all melanoma 
patients are B-raf mutant-negative and do not show responsive-
ness. About half of B-raf-positive patients show responses, but 
most of these eventually fail. Also, dose-limiting adverse events 
occur in about 40% of patients treated with B-raf. 24,25
Regional chemotherapy for locally recurrent or in-transit 
metastatic melanoma distal to the axilla or groin has been 
shown to be an effective treatment option in many situations 
where surgical resection is not possible or has failed.13,18 
Isolated limb perfusion has been used extensively interna-
tionally, whereas ILI has become widely used by specialist 
melanoma centers in Australia, with gradual interest interna-
tionally.26,27 The advantages of ILI are its technical simplicity 
and practicality, good tolerability in patients (especially the 
elderly), and the relative ease of repeating the procedure(s). 
ILI also has a relatively low complication rate compared with 
isolated limb perfusion, and does not require specialized extra-
corporeal bypass facilities, invasive surgery, or blood transfu-
sion.18 Further, the reduced operative time and cost required 
per procedure makes it economically more attractive for health 
budgets than isolated limb perfusion. Lower rates of limb 
toxicity and morbidity, including compartment syndrome, 
peripheral neuropathy, infection, and venous thrombosis, are 
also significant additional economic advantages.17
The current analysis shows that the patients treated at the 
Adelaide Melanoma Unit experience very low levels of limb 
toxicity, with only one significant long-term complication 
recorded so far. However, this occurred in a patient with a 
specific venous stasis problem that was only reported after 
ILI. Our overall toxicity rates assessing each ILI episode as 
an independent event (n = 28) demonstrated relatively low 
morbidity (75% Wieberdink grade 1 or 2). For overall out-
comes (n = 20) after the final ILI, the toxicity profile (grade 1, 
5%; grade 2, 75%; grade 3, 10%; grade 4, 10%) was not 
significantly different from either independently analyzed 
ILI procedures or first ILI procedures. This indicates that the 
post-ILI toxicity profile remained similar regardless of the 
number of procedures that were performed per patient, which 
is in accordance with previous reports on repeat ILI.28 The 
median follow-up period after initial ILI for all 20 patients 
was 15.9 (2.7–121.4) months, providing a good indication 
that successful longer-term results can be achieved.
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After the final ILI, there was an overall clinical response 
rate of 70%, with a complete response rate of 35% and a 
partial response rate of 35%. Stable disease was seen in 20% 
and progressive disease in 10% of patients. If stable disease 
was included, the overall “clinically effective” response rate 
was 90%, where any clinically significant or meaningful 
measurable response was observed.
Our response rates compare favorably with previously 
published ILI studies. At the time of publication, the larg-
est ILI study, performed by the Sydney Melanoma Unit, 
consisted of 185 patients. 17 That study showed an overall 
response rate of 84% (complete response 38%, partial 
response 46%) using a technique similar to that used in this 
analysis after one ILI. After repeated ILI procedures (n = 48), 
the overall response was 83% (complete response 23% and 
partial response 60%).28 The first and to date only multicenter 
study investigating the ILI procedure showed a slightly lower 
but still satisfactory response rate in comparison with the 
Sydney Melanoma Unit study with an overall response rate 
of 64% (complete response 31%, partial response 33%), after 
one or more ILI procedures.26
Measurement of visible melanoma nodules or deposits 
was performed with good reproducibility by measuring in two 
directions perpendicular to each other. However, for deeper 
deposits, imaging was required and this was done by either 
Doppler ultrasound or computed tomography scanning. An 
alternative would be to use contrast-enhanced ultrasound or 
dynamic contrast-enhanced ultrasonography for evaluations 
using microbubble contrast.29 However, the most ideal lesions for 
dynamic contrast-enhanced ultrasonography are those that are 
over 2 cm in size, with sufficient necrosis and more vasculariza-
tion. Smaller deposits can be more difficult to evaluate, and were 
the main type of in-transit deposit encountered in our study.
ILI chemotherapy could be combined with approved 
or experimental systemic therapies, such as interleukin-2, 
standard chemotherapy, radiotherapy, or serine–threonine 
protein kinase B-Raf inhibitory antibodies (B-Raf), Cytotoxic 
T lymphocyte associated antigen-4 (CTLA-4), mitogen-acti-
vated protein kinase kinase (MEK) Programmed cell Death 
Receptor-1 (PD-1), Programmed cell Death Ligand-1 (PD-
L1) inhibitor therapy,  or local intra-lesional therapies such 
as coxsackie virus or rose bengal, and be practice-changing. 
ILI using non-cytotoxic agents, perhaps including some of 
those above, might be explored.
Although ILI is essentially a regional local treatment 
confined to the melanoma-affected limb, long-term survival is 
not uncommon. This raises the distinct possibility of  systemic 
immune modulation from “autovaccination” events as a result 
of tumor necrosis induced by ILI chemotherapy, which has 
been proposed previously.30 Similar reports have been made 
for other local therapies associated with direct lesional injec-
tion of melanoma metastases, and topical desensitising thera-
pies such as diphencyprone (DPCP), where “bystander”-type 
regressions have been noted in noninjected metastases.31–34
Conclusion
The current analysis of our procedures indicates that ILI is a 
particularly useful method for controlling metastatic limb mel-
anoma, with high efficacy and results comparable with those 
reported using isolated limb perfusion chemotherapy regimens, 
avoiding a more invasive and costly procedure. ILI offers the 
advantage of being a relatively simple method with lower mor-
bidity. Our findings validate previous studies using ILI. Larger 
multicenter studies are required to investigate the true efficacy 
of ILI for treating locally advanced melanoma confined to the 
limb. Further work on the ILI method is currently required to 
improve and refine this promising technique for treatment of 
limb melanoma. Long-term survivors are reported after ILI. 
Combination therapy using ILI chemotherapy and other sys-
temic therapies may be a useful future direction.
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